Huntington's disease: the coming of age

被引:34
|
作者
Pandey, Mritunjay [1 ]
Rajamma, Usha [2 ]
机构
[1] NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA
[2] Inter Univ Ctr Biomed Res & Super Specialty Hosp, Kottayam 686009, Kerala, India
基金
美国国家卫生研究院;
关键词
Huntington's disease; neurodegeneration; autosomal dominant disorder; huntingtin; pathophysiology; neurochemistry; therapeutic intervention; INCLUSION-BODY FORMATION; MUTANT HUNTINGTIN; NEURONAL LOSS; HD GENE; BEHAVIORAL ABNORMALITIES; CREATINE SUPPLEMENTATION; MITOCHONDRIAL FISSION; SUBCORTICAL DEMENTIA; PROJECTION NEURONS; AXONAL-TRANSPORT;
D O I
10.1007/s12041-018-0957-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Huntington's disease (HD) is caused due to an abnormal expansion of polyglutamine repeats in the first exon of huntingtin gene. The mutation in huntingtin causes abnormalities in the functioning of protein, leading to deleterious effects ultimately to the demise of specific neuronal cells. The disease is inherited in an autosomal dominant manner and leads to a plethora of neuropsychiatric behaviour and neuronal cell death mainly in striatal and cortical regions of the brain, eventually leading to death of the individual. The discovery of the mutant gene led to a surge in molecular diagnostics of the disease and in making different transgenic models in different organisms to understand the function of wild-type and mutant proteins. Despite difficult challenges, there has been a significant increase in understanding the functioning of the protein in normal and other gain-of-function interactions in mutant form. However, there have been no significant improvements in treatments of the patients suffering from this ailment and most of the treatment is still symptomatic. HD warrants more attention towards better understanding and treatment as more advancement in molecular diagnostics and therapeutic interventions are available. Several different transgenic models are available in different organisms, ranging from fruit flies to primate monkeys, for studies on understanding the pathogenicity of the mutant gene. It is the right time to assess the advancement in the field and try new strategies for neuroprotection using key pathways as target. The present review highlights the key ingredients of pathology in the HD and discusses important studies for drug trials and future goals for therapeutic interventions.
引用
收藏
页码:649 / 664
页数:16
相关论文
共 50 条
  • [41] Huntington's disease
    Dose, M
    PSYCHIATRISCHE PRAXIS, 1996, 23 (03) : 107 - 108
  • [42] Biotech's Coming of Age
    Glick, J. Leslie
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2011, 31 (02): : 6 - 7
  • [43] Huntington's disease
    Rollnik, J. D.
    NERVENARZT, 2015, 86 (06): : 725 - 735
  • [44] Huntington's disease
    Leenders, KL
    MOVEMENT DISORDERS, 2002, 17 : S7 - S7
  • [45] Huntington's disease
    Arroyave, Pilar
    Riveros, Monica
    UNIVERSITAS MEDICA, 2006, 47 (02): : 121 - 130
  • [46] Huntington's disease
    不详
    CURRENT BIOLOGY, 1998, 8 (19) : R672 - R672
  • [47] Huntington's disease
    Ha, Ainhi D.
    Fung, Victor S. C.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) : 491 - 498
  • [48] Huntington's disease
    Craufurd, D
    PRENATAL DIAGNOSIS, 1996, 16 (13) : 1237 - 1245
  • [49] Huntington's Disease
    Finkbeiner, Steven
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2011, 3 (06): : 1 - 24
  • [50] Huntington's disease
    Cha, JHJ
    MOVEMENT DISORDERS, 2002, 17 : S8 - S8